Hong-feng Gou - Publications

Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.

Journal: International immunopharmacology

Published: September 20, 2023

Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma.

Journal: Frontiers in pharmacology

Published: March 21, 2023

Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: July 05, 2021

Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study.

Journal: The oncologist

Published: December 27, 2020

First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component.

Journal: Cancer medicine

Published: November 20, 2020

Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adjuvant Setting for Signet Ring Cell Containing Gastric Cancer.

Journal: Frontiers in oncology

Published: June 12, 2020

ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma.

Journal: Medicine

Published: April 04, 2020

Correction: Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis.

Journal: Cell death & disease

Published: September 28, 2019

Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.

Journal: Human gene therapy

Published: January 30, 2019

S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.

Journal: The oncologist

Published: September 09, 2018

Intraperitoneal oxaliplatin administration inhibits the tumor immunosuppressive microenvironment in an abdominal implantation model of colon cancer.

Journal: Molecular medicine reports

Published: November 19, 2017

Improved therapeutic potential of MSCs by genetic modification.

Journal: Gene therapy

Published: October 10, 2017